Search Results

Aurélien Rizk About Dr. Aurélien Rizk "Dr. Aurélien Rizk is a scientist and entrepreneur in drug discovery. Aurélien Rizk co-founded Algorizk, a company that created real-time physics simulations for education Aurélien Rizk on the web InterAx Biotech Paul Scherrer Institut The Org LinkedIn Google Scholar Dr. Rizk discussed the differences between academia and the biotech industry, with Aurelien Rizk sharing

Aurélien Rizk is Chief Technology Officer at InterAx Biotech. Oprea , Thomas Sakmar , Aurelien Rizk & Yaroslav Nikolaev .

Expert support, trusted CROs, and ready-to-use tools to accelerate GPCR drug discovery, reduce risk, our nonprofit team for expert guidance, trusted CRO collaborations, and field-tested tools that de-risk From pipeline acceleration and investment de-risking to CRO differentiation — turning GPCR complexity Book a Strategy Call → Our Core Support Areas Discovery Consulting & Strategy Expert guidance to de-risk you are in your discovery journey, the Foundry helps GPCR biotech companies move faster and reduce risk

Fuel Discovery VC Due Diligence & De-risking For Venture Capital Firms De-risk GPCR Investments: Identify Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic focused, scientific expertise that accelerates complex GPCR discovery programs, ensuring clarity and de-risking Foundation of Every Successful Partnership My advisory is built on principles that ensure clarity, minimize risk This ensures robust, defensible decisions that de-risk your program from early discovery to regulatory

understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk

nice to have” tests that stall timelines without payoff Match experiments to the specific phase and risk tolerance of the asset De-risk Your CRO Strategy I evaluate, select, and manage CROs that are fit-for-purpose—saving

patients: securing funding aligned with translational potential, defining research directions that balance risk

biochemists Celtarys empowers medicinal biochemists by providing innovative fluorescent probes that de-risk Fluorescent Probes Innovative fluorescent probes that de-risk the pre-clinical drug discovery phase with

Each program appears to increase optionality and reduce risk. 👉 This is where str Attila Foris Feb 23

You pay $450 if you stay. 1,400+ Scientists in the community 200+ Recordings $0 Net risk if you convert

school 10:23 Army service, social work in Nicaragua, and the civil war that reframed resources and risk 2013 prize announcement "If you willingly put yourself in a situation where you're willing to take risks

Metabolism – Distribution, renal/hepatic pathways, and elimination 🔹 Safety First – Identifying toxicity risks

.” – Chuck DeWeese Jumping Off the Cliff: The Entrepreneur’s Leap Joe shares the risks of launching a

Jose Rizo-Rey as a graduate student to elucidate the mechanisms of neurotransmitter release.

Navigating Serendipity and Risk in Discovery — From the accidental observation of GPCR dimers to negative

pharmacoepidemiology to study how human genetic variation in GPCR drug targets shapes drug response and disease risk

For Hay, who has studied RAMPs since they were first described and when working on them was a high-risk

decisions of his career - a bet that the community would respond and the opportunity would justify the risk

developed a machine learning predictor trained on intensely bitter compounds that can flag bitterness risk

You assume all risks associated with Your Content, including anyone's reliance on its quality, accuracy

You assume all risks associated with Your Content, including anyone's reliance on its quality, accuracy

DISCLAIMER OF WARRANTIES: CUSTOMER AGREES THAT HE/SHE/IT IS MAKING USE OF THE SERVICES AT HIS/SHE/ITS OWN RISK

One of the risks with new technologies is that people sometimes build the research question around the